JP2025092589A5 - - Google Patents

Info

Publication number
JP2025092589A5
JP2025092589A5 JP2025053695A JP2025053695A JP2025092589A5 JP 2025092589 A5 JP2025092589 A5 JP 2025092589A5 JP 2025053695 A JP2025053695 A JP 2025053695A JP 2025053695 A JP2025053695 A JP 2025053695A JP 2025092589 A5 JP2025092589 A5 JP 2025092589A5
Authority
JP
Japan
Prior art keywords
seq
variable region
chain variable
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025053695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025092589A (ja
Filing date
Publication date
Priority claimed from PCT/JP2021/009798 external-priority patent/WO2021182573A1/ja
Application filed filed Critical
Publication of JP2025092589A publication Critical patent/JP2025092589A/ja
Publication of JP2025092589A5 publication Critical patent/JP2025092589A5/ja
Pending legal-status Critical Current

Links

JP2025053695A 2020-03-12 2025-03-27 癌の治療及び/又は予防のための医薬品 Pending JP2025092589A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2020043021 2020-03-12
JP2020043021 2020-03-12
PCT/JP2021/009798 WO2021182573A1 (ja) 2020-03-12 2021-03-11 癌の治療及び/又は予防のための医薬品
JP2021532006A JP7797875B2 (ja) 2020-03-12 2021-03-11 癌の治療及び/又は予防のための医薬品

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021532006A Division JP7797875B2 (ja) 2020-03-12 2021-03-11 癌の治療及び/又は予防のための医薬品

Publications (2)

Publication Number Publication Date
JP2025092589A JP2025092589A (ja) 2025-06-19
JP2025092589A5 true JP2025092589A5 (enExample) 2026-02-02

Family

ID=77671643

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532006A Active JP7797875B2 (ja) 2020-03-12 2021-03-11 癌の治療及び/又は予防のための医薬品
JP2025053695A Pending JP2025092589A (ja) 2020-03-12 2025-03-27 癌の治療及び/又は予防のための医薬品

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021532006A Active JP7797875B2 (ja) 2020-03-12 2021-03-11 癌の治療及び/又は予防のための医薬品

Country Status (7)

Country Link
US (1) US20230129035A1 (enExample)
EP (1) EP4119156A4 (enExample)
JP (2) JP7797875B2 (enExample)
KR (1) KR20220152318A (enExample)
BR (1) BR112022018157A2 (enExample)
CA (1) CA3175137A1 (enExample)
WO (1) WO2021182573A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2322221E (pt) * 2008-08-05 2014-09-19 Toray Industries Composição farmacêutica para tratamento e prevenção de cancro
CA3227706A1 (en) * 2021-07-27 2023-02-02 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3227698A1 (en) * 2021-07-27 2023-02-02 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JPWO2023008461A1 (enExample) * 2021-07-27 2023-02-02
JPWO2024043252A1 (enExample) * 2022-08-24 2024-02-29
AU2023329564A1 (en) * 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20250052364A (ko) * 2022-08-24 2025-04-18 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
WO2024190815A1 (ja) * 2023-03-14 2024-09-19 第一三共株式会社 抗cdh6抗体-薬物コンジュゲートとvegf阻害剤の組み合わせ

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
KR100261941B1 (ko) 1994-07-13 2000-07-15 나가야마 오사무 사람의 인터루킨-8에 대한 재구성 사람항체
AU752730B2 (en) 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
DE10359795A1 (de) 2003-12-19 2005-07-21 Bayer Technology Services Gmbh Strangverdampfervorrichtung
PT2322221E (pt) 2008-08-05 2014-09-19 Toray Industries Composição farmacêutica para tratamento e prevenção de cancro
WO2011005481A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
US8642292B2 (en) 2009-09-22 2014-02-04 Probiogen Ag Process for producing molecules containing specialized glycan structures
PL2532364T3 (pl) 2010-02-04 2016-11-30 Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi
US8709418B2 (en) 2010-02-04 2014-04-29 Toray Industries, Inc. Pharmaceutical composition for treating CAPRIN-1 expressing cancer
CA2788716C (en) 2010-02-04 2019-06-18 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
KR101805520B1 (ko) 2010-02-04 2017-12-07 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
BR112012018943A8 (pt) * 2010-02-04 2017-12-19 Toray Industries medicamento e método para o tratamento e/ou prevenção de um câncer
ES2583627T3 (es) * 2010-02-04 2016-09-21 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención del cáncer
MX341925B (es) 2010-03-29 2016-09-07 Zymeworks Inc Anticuerpos con funcion efectora suprimida o mejorada.
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
ES2634249T3 (es) 2011-08-04 2017-09-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
WO2013018886A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 膵臓癌の治療及び/又は予防用医薬組成物
MX348578B (es) 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
HUE030137T2 (en) 2011-08-04 2017-04-28 Toray Industries Pharmaceutical preparation for the treatment and / or prevention of cancer
RU2624049C2 (ru) 2011-08-04 2017-06-30 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и профилактики злокачественной опухоли
US9273130B2 (en) 2012-02-21 2016-03-01 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
MX360211B (es) 2012-02-21 2018-10-24 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CA2864999C (en) * 2012-02-21 2020-06-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
EP2818483B1 (en) 2012-02-21 2017-08-02 Toray Industries, Inc. Medicinal composition for treating and/or preventing cancer
CA2869123C (en) 2012-03-30 2021-03-16 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment of gallbladder cancer
CN104220095B (zh) 2012-03-30 2016-09-07 东丽株式会社 肝癌的治疗和/或预防用药物组合物
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
EP3031826B1 (en) * 2013-08-09 2018-10-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
KR20200019865A (ko) 2017-06-22 2020-02-25 노파르티스 아게 암 치료에 사용하기 위한 il-1베타 결합 항체
BR112020019935A2 (pt) 2018-03-30 2021-01-26 Toray Industries, Inc. medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método de tratamento e/ou prevenção do câncer
JP7103097B2 (ja) 2018-09-13 2022-07-20 トヨタ自動車株式会社 燃料電池車両

Similar Documents

Publication Publication Date Title
JP2025092589A5 (enExample)
JP2020510422A5 (enExample)
US9994632B2 (en) Humanized or affinity-matured anti Ang-2 antibody and uses thereof
JP2019535250A5 (enExample)
JP2018508483A5 (enExample)
JP2017535257A5 (enExample)
JP2020514310A5 (enExample)
JP2013527762A5 (enExample)
JP2017514461A5 (enExample)
IL253462B (en) Cancer treatment with monoclonal antibodies against latency-associated peptide
JP2018503365A5 (enExample)
JP2014530215A5 (enExample)
HRP20180262T1 (hr) Monoklonska anti-gt468 protutijela za liječenje karcinoma
JP2014522850A5 (enExample)
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
CA3208455A1 (en) Novel anti-gremlin1 antibodies
CN118871467A (zh) 抗pd-l2抗体
JPWO2021104371A5 (enExample)
JPWO2023008462A5 (enExample)
US20240309116A1 (en) Antibodies against ror1 and uses thereof
JPWO2020102387A5 (enExample)
JPWO2023008461A5 (enExample)
CA3160526A1 (en) Pharmaceutical combination and use thereof
RU2025104409A (ru) Лекарственное средство для лечения и/или предупреждения злокачественной опухоли
RU2025104410A (ru) Лекарственное средство для лечения и/или предупреждения злокачественной опухоли